Publisher Correction: Novel immunotherapeutics against LGR5 to target multiple cancer types

Hung-Chang Chen^#^{1

2}, Nico Mueller^#¹, Katherine Stott³, Chrysa Kapeni¹, Eilidh Rivers^{3

4}, Carolin M Sauer¹, Flavio Beke¹, Stephen J Walsh^{5

6}, Nicola Ashman^{5

7}, Louise O'Brien¹, Amir Rafati Fard³, Arman Ghodsinia³, Changtai Li³, Fadwa Joud¹, Olivier Giger⁸, Inti Zlobec⁹, Ioana Olan¹, Sarah J Aitken^{10

11}, Matthew Hoare¹, Richard Mair¹, Eva Serrao¹, James D Brenton¹, Alicia Garcia-Gimenez¹², Simon E Richardson¹², Brian Huntly¹², David R Spring⁵, Mikkel-Ole Skjoedt^{13

14

15}, Karsten Skjødt¹⁶, Marc de la Roche¹⁷, Maike de la Roche¹⁸

Affiliations

¹ University of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
² Astra Zeneca, Cambridge, UK.
³ University of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK.
⁴ MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.
⁵ University of Cambridge, Yusuf Hamied Department of Chemistry, Lensfield Road, Cambridge, CB2 1EW, UK.
⁶ Bicycle Therapeutics, Cambridge, UK.
⁷ Charles River Laboratories, Saffron Walden, UK.
⁸ University of Cambridge, Department of Pathology, Tennis Court Road, Cambridge, CB2 1QP, UK.
⁹ Institute of Pathology, University of Bern, Murtenstrasse 31, CH-3008, Bern, Switzerland.
¹⁰ University of Cambridge, MRC Toxicology Unit, Tennis Court Road, Cambridge, CB2 1QR, UK.
¹¹ Department of Histopathology, Cambridge University Hospitals, NHS Foundation Trust, Main Drive, Cambridge, CB2 0QQ, UK.
¹² University of Cambridge, Department of Haematology, Puddicombe Way, Cambridge, CB2 0AW, UK.
¹³ Rigshospitalet-University Hospital Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
¹⁴ Institute of Immunology and Microbiology, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.
¹⁵ Novo Nordisk, Måløv, Denmark.
¹⁶ University of Southern Denmark Campusvej 55, Odense M, DK-5230, Denmark.
¹⁷ University of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK. mad58@cam.ac.uk.
¹⁸ University of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK. maike.delaroche@cruk.cam.ac.uk.

^# Contributed equally.

PMID: 39322863
PMCID: PMC11555075
DOI: 10.1038/s44321-024-00139-6

Published Erratum

Publisher Correction: Novel immunotherapeutics against LGR5 to target multiple cancer types

Hung-Chang Chen et al. EMBO Mol Med. 2024 Nov.

. 2024 Nov;16(11):3026.

doi: 10.1038/s44321-024-00139-6.

Authors

Affiliations

¹ University of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
² Astra Zeneca, Cambridge, UK.
³ University of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK.
⁴ MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.
⁵ University of Cambridge, Yusuf Hamied Department of Chemistry, Lensfield Road, Cambridge, CB2 1EW, UK.
⁶ Bicycle Therapeutics, Cambridge, UK.
⁷ Charles River Laboratories, Saffron Walden, UK.
⁸ University of Cambridge, Department of Pathology, Tennis Court Road, Cambridge, CB2 1QP, UK.
⁹ Institute of Pathology, University of Bern, Murtenstrasse 31, CH-3008, Bern, Switzerland.
¹⁰ University of Cambridge, MRC Toxicology Unit, Tennis Court Road, Cambridge, CB2 1QR, UK.
¹¹ Department of Histopathology, Cambridge University Hospitals, NHS Foundation Trust, Main Drive, Cambridge, CB2 0QQ, UK.
¹² University of Cambridge, Department of Haematology, Puddicombe Way, Cambridge, CB2 0AW, UK.
¹³ Rigshospitalet-University Hospital Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
¹⁴ Institute of Immunology and Microbiology, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.
¹⁵ Novo Nordisk, Måløv, Denmark.
¹⁶ University of Southern Denmark Campusvej 55, Odense M, DK-5230, Denmark.
¹⁷ University of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK. mad58@cam.ac.uk.
¹⁸ University of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK. maike.delaroche@cruk.cam.ac.uk.

^# Contributed equally.

PMID: 39322863
PMCID: PMC11555075
DOI: 10.1038/s44321-024-00139-6

Abstract

PubMed Disclaimer

Erratum for

Novel immunotherapeutics against LGR5 to target multiple cancer types.
Chen HC, Mueller N, Stott K, Kapeni C, Rivers E, Sauer CM, Beke F, Walsh SJ, Ashman N, O'Brien L, Rafati Fard A, Ghodsinia A, Li C, Joud F, Giger O, Zlobec I, Olan I, Aitken SJ, Hoare M, Mair R, Serrao E, Brenton JD, Garcia-Gimenez A, Richardson SE, Huntly B, Spring DR, Skjoedt MO, Skjødt K, de la Roche M, de la Roche M. Chen HC, et al. EMBO Mol Med. 2024 Sep;16(9):2233-2261. doi: 10.1038/s44321-024-00121-2. Epub 2024 Aug 21. EMBO Mol Med. 2024. PMID: 39169164 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: Novel immunotherapeutics against LGR5 to target multiple cancer types

Affiliations

Publisher Correction: Novel immunotherapeutics against LGR5 to target multiple cancer types

Authors

Affiliations

Abstract

Erratum for

Publication types

LinkOut - more resources

Full Text Sources